Status:
UNKNOWN
Expression of LC3-I, LC3-II & Beclin 1 in Vitiligo
Lead Sponsor:
Cairo University
Conditions:
Autophagy
Eligibility:
All Genders
12+ years
Phase:
NA
Brief Summary
The exact mechanism of impairment of autophagy in vitiligo has not yet been determined.
Eligibility Criteria
Inclusion
- • Patients with non-segmental vitiligo whether active or stable.
- Age above 12 years.
- Both sexes.
Exclusion
- • Patients should not use any topical or systemic treatment at least 6 weeks before inclusion into the study.
- Patients having other autoimmune disease, heart disease, liver disease, kidney disease, neurological disorder, cancer, active infection or any chronic disease.
- Pregnancy or breast feeding for female patients.
Key Trial Info
Start Date :
January 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2018
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT03371758
Start Date
January 1 2017
End Date
May 1 2018
Last Update
January 23 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Maha Fathy Elmasry
Cairo, Egypt